Shenzhen Simmogen Pharmaceutical Co., Ltd. received approval for clinical trials of its innovative siRNA drug SAL0195. The drug targets elevated lipoprotein(a) and has shown long-acting efficacy in preclinical models. Successful development could offer new treatment options for unmet clinical needs in chronic diseases.
Summary generated by AI · Always verify with source document
Stock Code: 002294
Stock Abbreviation: Simmogen
Announcement No.: 2026-063
Shenzhen Simmogen Pharmaceutical Co., Ltd.
Announcement on Obtaining Clinical Trial Approval for SAL0195
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or material omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.